Citations (52)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Ana C. Veneziani, Eduardo Gonzalez-Ochoa & Amit M. Oza. (2023) Emerging peptide therapeutics for the treatment of ovarian cancer. Expert Opinion on Emerging Drugs 28:2, pages 129-144.
Read now
Read now
Mi Yang, Xiufeng Liu, Cheng Zhang, Feng Liao, Zixiong Li, Xianwen Luo, Yiran Sun & Chao Chen. (2019) A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients. Cancer Management and Research 11, pages 8869-8876.
Read now
Read now
Carla Souza, Diogo Silva Pellosi & Antonio Claudio Tedesco. (2019) Prodrugs for targeted cancer therapy. Expert Review of Anticancer Therapy 19:6, pages 483-502.
Read now
Read now
Articles from other publishers (49)
Mary Towner & Jenna Marcus. (2024) Antibody–Drug Conjugates for the Treatment of Gynecologic Cancer. Advances in Oncology.
Crossref
Crossref
Ritchu Babbar, Vanya, Aarti Bassi, Rashmi Arora, Ankur Aggarwal, Pranay Wal, Sunil Kumar Dwivedi, Salma Alolayan, Monica Gulati, Celia Vargas-De-La-Cruz, Tapan Behl & Shreesh Ojha. (2023) Understanding the promising role of antibody drug conjugates in breast and ovarian cancer. Heliyon 9:11, pages e21425.
Crossref
Crossref
Jia Mai, Limei Wu, Ling Yang, Ting Sun, Xiaojuan Liu, Rutie Yin, Yongmei Jiang, Jinke Li & Qintong Li. (2023) Therapeutic strategies targeting folate receptor α for ovarian cancer. Frontiers in Immunology 14.
Crossref
Crossref
Rebecca L. Porter & Ursula A. Matulonis. (2023) Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer. Expert Review of Anticancer Therapy 23:8, pages 783-796.
Crossref
Crossref
Rebecca Newhouse, Ellen Nelissen, Karim Hussien El-Shakankery, Ewelina Rogozińska, Esme Bain, Susana Veiga & Jo Morrison. (2023) Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2023:7.
Crossref
Crossref
Yu Jun Lim, Pei Sze Clarissa Lau, Shi Xuan Low, Shong Li Ng, Min Yee Ong, Huey Ming Pang, Zheng Yang Lee, Hui Yin Yow, Sharina Binti Hamzah, Renukha Sellappans & Jhi Biau Foo. (2023) How Far Have We Developed Antibody–Drug Conjugate for the Treatment of Cancer?. Drugs and Drug Candidates 2:2, pages 377-421.
Crossref
Crossref
Joan Tymon-Rosario, Megan Gorman, Debra L. Richardson, Christina Washington & Alessandro D. Santin. (2023) Advances in antibody-drug conjugates for gynecologic malignancies. Current Opinion in Obstetrics & Gynecology 35:1, pages 6-14.
Crossref
Crossref
Olivia Young, Nealie Ngo, Leslie Lin, Laura Stanbery, Justin Fortune Creeden, Danae Hamouda & John Nemunaitis. (2023) Folate Receptor as a Biomarker and Therapeutic Target in Solid Tumors. Current Problems in Cancer 47:1, pages 100917.
Crossref
Crossref
Eduardo Gonzalez-Ochoa, Ana C Veneziani & Amit M Oza. (2023) Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer. Clinical Medicine Insights: Oncology 17.
Crossref
Crossref
Michael J. Birrer & Brandon Roane. 2023. DiSaia and Creasman Clinical Gynecologic Oncology. DiSaia and Creasman Clinical Gynecologic Oncology
489
505.e5
.
Evelyn O'Sullivan Greene & Frances Shiely. (2022) Recording and reporting of recruitment strategies in trial protocols, registries, and publications was nonexistent. Journal of Clinical Epidemiology 152, pages 248-256.
Crossref
Crossref
Julia Schnoell, Bernhard J Jank, Lorenz Kadletz-Wanke, Stefan Stoiber, Elisabeth Gurnhofer, Michaela Schlederer, Gregor Heiduschka & Lukas Kenner. (2022) Protein Expression of Folate Receptor Alpha in Adenoid Cystic Carcinoma of the Head and Neck. OncoTargets and Therapy Volume 15, pages 531-538.
Crossref
Crossref
Yiming Jin, Megan A. Schladetsch, Xueting Huang, Marcy J. Balunas & Andrew J. Wiemer. (2022) Stepping forward in antibody-drug conjugate development. Pharmacology & Therapeutics 229, pages 107917.
Crossref
Crossref
Cristina Martín-Sabroso, Ana Isabel Torres-Suárez, Mario Alonso-González, Ana Fernández-Carballido & Ana Isabel Fraguas-Sánchez. (2021) Active Targeted Nanoformulations via Folate Receptors: State of the Art and Future Perspectives. Pharmaceutics 14:1, pages 14.
Crossref
Crossref
Michelle McMullen, Ainhoa Madariaga & Stephanie Lheureux. (2021) New approaches for targeting platinum-resistant ovarian cancer. Seminars in Cancer Biology 77, pages 167-181.
Crossref
Crossref
Junzo Hamanishi, Nobuhiro Takeshima, Noriyuki Katsumata, Kimio Ushijima, Tadashi Kimura, Satoshi Takeuchi, Koji Matsumoto, Kimihiko Ito, Masaki Mandai, Hidekatsu Nakai, Noriaki Sakuragi, Hidemichi Watari, Nobutaka Takahashi, Hidenori Kato, Kosei Hasegawa, Kan Yonemori, Mika Mizuno, Kazuhiro Takehara, Hitoshi Niikura, Takashi Sawasaki, Sari Nakao, Toshiaki Saito, Takayuki Enomoto, Satoru Nagase, Nao Suzuki, Takashi Matsumoto, Eiji Kondo, Kenzo Sonoda, Satomi Aihara, Yoichi Aoki, Aikou Okamoto, Hirokuni Takano, Hiroshi Kobayashi, Hisamori Kato, Yoshito Terai, Akira Takazawa, Yusuke Takahashi, Yoshinobu Namba, Daisuke Aoki, Keiichi Fujiwara, Toru Sugiyama & Ikuo Konishi. (2021) Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA). Journal of Clinical Oncology 39:33, pages 3671-3681.
Crossref
Crossref
Zhe Wang, Fenghua Meng & Zhiyuan Zhong. (2021) Emerging targeted drug delivery strategies toward ovarian cancer. Advanced Drug Delivery Reviews 178, pages 113969.
Crossref
Crossref
David M. O’Malley & Corinne A. Calo. (2021) Progress in Gynecologic Cancers with Antibody Drug Conjugates. Current Oncology Reports 23:8.
Crossref
Crossref
Corinne A. Calo & David M. O’Malley. (2020) Antibody-drug conjugates for the treatment of ovarian cancer. Expert Opinion on Biological Therapy 21:7, pages 875-887.
Crossref
Crossref
K.N. Moore, A.M. Oza, N. Colombo, A. Oaknin, G. Scambia, D. Lorusso, G.E. Konecny, S. Banerjee, C.G. Murphy, J.L. Tanyi, H. Hirte, J.A. Konner, P.C. Lim, M. Prasad-Hayes, B.J. Monk, P. Pautier, J. Wang, A. Berkenblit, I. Vergote & M.J. Birrer. (2021) Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Annals of Oncology 32:6, pages 757-765.
Crossref
Crossref
Oladapo O. Yeku, Thapi Dharma Rao, Ian Laster, Artem Kononenko, Terence J. Purdon, Pei Wang, Ziyou Cui, Hong Liu, Renier J. Brentjens & David Spriggs. (2021) Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition. Frontiers in Immunology 12.
Crossref
Crossref
M. Knödler & J.F. Buyel. (2021) Plant-made immunotoxin building blocks: A roadmap for producing therapeutic antibody-toxin fusions. Biotechnology Advances 47, pages 107683.
Crossref
Crossref
Joan Tymon-Rosario, Burak Zeybek & Alessandro D. Santin. (2021) Novel antibody–drug conjugates: current and future roles in gynecologic oncology. Current Opinion in Obstetrics & Gynecology 33:1, pages 26-33.
Crossref
Crossref
Lidya SalimJean-Paul Desaulniers. (2021) To Conjugate or to Package? A Look at Targeted siRNA Delivery Through Folate Receptors. Nucleic Acid Therapeutics 31:1, pages 21-38.
Crossref
Crossref
Rebecca C. Arend, Amy Jackson-Fisher, Ira A. Jacobs, Jeffrey Chou & Bradley J. Monk. (2021) Ovarian cancer: new strategies and emerging targets for the treatment of patients with advanced disease. Cancer Biology & Therapy 22:2, pages 89-105.
Crossref
Crossref
Annie Ren, Ioannis Prassas, Vijithan Sugumar, Antoninus Soosaipillai, Marcus Bernardini, Eleftherios P Diamandis & Vathany Kulasingam. (2021) Comparison of two multiplexed technologies for profiling >1,000 serum proteins that may associate with tumor burden. F1000Research 10, pages 509.
Crossref
Crossref
Nirupama Sabnis, Ezek Mathew, Akpedje Dossou, Amy Zheng, Bhavani Nagarajan, Rafal Fudala & Andras G. Lacko. 2021. Overcoming Drug Resistance in Gynecologic Cancers. Overcoming Drug Resistance in Gynecologic Cancers
77
126
.
Meinusha Govindarajan, Christoph Wohlmuth, Matthew Waas, Marcus Q. Bernardini & Thomas Kislinger. (2020) High-throughput approaches for precision medicine in high-grade serous ovarian cancer. Journal of Hematology & Oncology 13:1.
Crossref
Crossref
Aranzazu Manzano & Alberto Ocaña. (2020) Antibody-Drug Conjugates: A Promising Novel Therapy for the Treatment of Ovarian Cancer. Cancers 12:8, pages 2223.
Crossref
Crossref
Nobumasa Tamura, Yutaka Fujiwara, Taiki Hashimoto, Hideaki Shiraishi, Shigehisa Kitano, Toshio Shimizu, Kazuyoshi Kuwano, Noboru Yamamoto & Noriko Motoi. (2020) Correlation between the expression of folate receptor alpha (FRα) and clinicopathological features in patients with lung adenocarcinoma. Lung Cancer 145, pages 152-157.
Crossref
Crossref
Valentina Boni, Manish R. Sharma & Amita Patnaik. (2020) The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and Payloads. American Society of Clinical Oncology Educational Book:40, pages e58-e74.
Crossref
Crossref
David M. O'Malley, Ursula A. Matulonis, Michael J. Birrer, Cesar M. Castro, Lucy Gilbert, Ignace Vergote, Lainie P. Martin, Gina M. Mantia-Smaldone, Antonio González Martin, Raquel Bratos, Richard T. Penson, Karim Malek & Kathleen N. Moore. (2020) Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecologic Oncology 157:2, pages 379-385.
Crossref
Crossref
Sara S Bashraheel, Alexander Domling & Sayed K Goda. (2020) Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine. Biomedicine & Pharmacotherapy 125, pages 110009.
Crossref
Crossref
Nuzhat Ahmed, Elif Kadife, Ali Raza, Mary Short, Paul T. Jubinsky & George Kannourakis. (2020) Ovarian Cancer, Cancer Stem Cells and Current Treatment Strategies: A Potential Role of Magmas in the Current Treatment Methods. Cells 9:3, pages 719.
Crossref
Crossref
Quan Guo, Qing Yang, Jun Li, Guipeng Liu, Igor Nikoulin & Steve Jia. (2020) Targeted therapy clinical trials in ovarian cancer: improved outcomes by gene mutation screening. Anti-Cancer Drugs 31:2, pages 101-109.
Crossref
Crossref
Jung‐Min Lee, Lori Minasian & Elise C. Kohn. (2019) New strategies in ovarian cancer treatment. Cancer 125:S24, pages 4623-4629.
Crossref
Crossref
Junpeng Qi, David Hymel, Christopher G. Nelson, Terrence R. BurkeJr.Jr. & Christoph Rader. (2019) Conventional and Chemically Programmed Asymmetric Bispecific Antibodies Targeting Folate Receptor 1. Frontiers in Immunology 10.
Crossref
Crossref
David M. Goldenberg & Robert M. Sharkey. (2019) Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan. mAbs 11:6, pages 987-995.
Crossref
Crossref
Sarah Nersesian, Haley Glazebrook, Jay Toulany, Stephanie R. Grantham & Jeanette E. Boudreau. (2019) Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer. Frontiers in Immunology 10.
Crossref
Crossref
Stephanie Lheureux, Marsela Braunstein & Amit M. Oza. (2019) Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA: A Cancer Journal for Clinicians 69:4, pages 280-304.
Crossref
Crossref
Michael J Birrer, Kathleen N Moore, Ilaria Betella & Richard C Bates. (2019) Antibody-Drug Conjugate-Based Therapeutics: State of the Science. JNCI: Journal of the National Cancer Institute 111:6, pages 538-549.
Crossref
Crossref
Ursula A. Matulonis, Michael J. Birrer, David M. O'Malley, Kathleen N. Moore, Jason Konner, Lucy Gilbert, Lainie P. Martin, Todd M. Bauer, Amit M. Oza, Karim Malek, Jan Pinkas & Stella K. Kim. (2019) Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody–Drug Conjugate Mirvetuximab Soravtansine. Clinical Cancer Research 25:6, pages 1727-1736.
Crossref
Crossref
Stephanie Lheureux, Charlie Gourley, Ignace Vergote & Amit M Oza. (2019) Epithelial ovarian cancer. The Lancet 393:10177, pages 1240-1253.
Crossref
Crossref
Eleonora Corbelli, Elisabetta Miserocchi, Alessandro Marchese, Chiara Giuffrè, Luigi Berchicci, Riccardo SacconiFrancesco Bandello & Giulio Maria Modorati. (2018) Ocular Toxicity of Mirvetuximab. Cornea 38:2, pages 229-232.
Crossref
Crossref
Daphne Stewart & Mihaela Cristea. (2019) Antibody–drug conjugates for ovarian cancer: current clinical development. Current Opinion in Obstetrics & Gynecology 31:1, pages 18-23.
Crossref
Crossref
Miroslav Miletín. (2019) Antibody‑Drug Conjugates. Klinická farmakologie a farmacie 32:4, pages 32-37.
Crossref
Crossref
Bhagyashri Joshi, Sukhada S. Shevade, Prajakta Dandekar & Padma V. Devarajan. 2019. Targeted Intracellular Drug Delivery by Receptor Mediated Endocytosis. Targeted Intracellular Drug Delivery by Receptor Mediated Endocytosis
407
431
.
Thomas Weimbs, Jonathan M Shillingford, Jacob Torres, Samantha L Kruger & Bryan C Bourgeois. (2018) Emerging targeted strategies for the treatment of autosomal dominant polycystic kidney disease. Clinical Kidney Journal 11:suppl_1, pages i27-i38.
Crossref
Crossref
Debra L. Richardson, Shelly M. Seward & Kathleen N. Moore. (2018) Antibody Drug Conjugates in the Treatment of Epithelial Ovarian Cancer. Hematology/Oncology Clinics of North America 32:6, pages 1057-1071.
Crossref
Crossref